UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Leukemia, 2019-10, Vol.33 (10), p.2531-2535

2019

Volltextzugriff (PDF)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Annals of the rheumatic diseases, 2020-11, Vol.79 (11), p.1478-1484

2020

Volltextzugriff (PDF)

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC

PloS one, 2023-10, Vol.18 (10), p.e0292307-e0292307

2023

Volltextzugriff (PDF)

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

European journal of drug metabolism and pharmacokinetics, 2018-10, Vol.43 (5), p.533-541

2018

Volltextzugriff (PDF)

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Investigational new drugs, 2020-10, Vol.38 (5), p.1472-1482

2020

Volltextzugriff (PDF)

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Investigational new drugs, 2021-02, Vol.39 (1), p.285-286

2021

Volltextzugriff (PDF)

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Investigational new drugs, 2021-02, Vol.39 (1), p.283-284

2021

Volltextzugriff (PDF)

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of clinical oncology, 2017-11, Vol.35 (31), p.3591-3600

2017

Volltextzugriff (PDF)

Single-crossover recombination and ancestral recombination trees

Journal of mathematical biology, 2014-05, Vol.68 (6), p.1371-1402

2014

Volltextzugriff (PDF)

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Lung cancer (Amsterdam, Netherlands), 2018-06, Vol.120, p.27-33

2018

Volltextzugriff (PDF)

Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix74

2017

Volltextzugriff (PDF)

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S216

2016

Volltextzugriff (PDF)

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS8574-TPS8574

2016

Volltextzugriff (PDF)

Single-crossover recombination in discrete time

Journal of mathematical biology, 2010-05, Vol.60 (5), p.727-760

2010

Volltextzugriff (PDF)

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S216-S216

2016

Volltextzugriff (PDF)

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients with Unresectable Malignant Pleural Mesothelioma

Clinical lung cancer, 2017-09, Vol.18 (5), p.589-593

2017

Volltextzugriff (PDF)

Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.8506-8506

2017

Volltextzugriff (PDF)

OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S329-S330

2017

Volltextzugriff (PDF)

Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS7612-TPS7612

2014

Volltextzugriff (PDF)

Single-crossover recombination and ancestral recombination trees

von Wangenheim, Ute

2011

Volltextzugriff (PDF)

Lateral root morphogenesis is dependent on the mechanical properties of the overlaying tissues

Proceedings of the National Academy of Sciences - PNAS, 2013-03, Vol.110 (13), p.5229-5234

2013

Volltextzugriff (PDF)

Schwache Interessen in der Selbstregulierung im Umweltrecht

Public Governance und Schwache Interessen, 2010

2010

Volltextzugriff (PDF)

Schwache Interessen in der Selbstregulierung im Umweltrecht

Public Governance und schwache Interessen, p.127-139

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(23)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Life Sciences & Biomedicine
(10)
Humans
(8)
Male
(7)
Oncology
(7)
Female
(6)
Middle Aged
(6)
Aged
(5)
Indoles - Administration & Dosage
(5)
Adult
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Pharmacology/toxicology
(4)
Aged, 80 And Over
(3)
Cisplatin - Administration & Dosage
(3)
Disease-Free Survival
(3)
Double-Blind Method
(3)
Lung Neoplasms - Drug Therapy
(3)
Medicine
(3)
Medicine & Public Health
(3)
Mesothelioma - Drug Therapy
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Single-crossover recombination and ancestral recombination trees

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Nintedanib plus pemetrexed/cisplatin in patients with MPM: Phase II findings from the placebo-controlled LUME-Meso trial

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM)

Single-crossover recombination in discrete time

Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM)

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients with Unresectable Malignant Pleural Mesothelioma

Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial

Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study

Single-crossover recombination and ancestral recombination trees

Lateral root morphogenesis is dependent on the mechanical properties of the overlaying tissues

Schwache Interessen in der Selbstregulierung im Umweltrecht

Schwache Interessen in der Selbstregulierung im Umweltrecht

Suchergebnisse filtern